



FOR IMMEDIATE RELEASE

NuSep Lodges 2 Gel Patents

SYDNEY, AUSTRALIA – 14th October 2010 – NuSep (ASX: NSP), wishes to advise that it has lodged two provisional gel patents.

These patent applications cover gel formulations that significantly improve both the shelf life and separation quality of the **ηUView** gels. The first commercial gel products using these new formulations will be launched in mid November 2010.

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteolQ software enabling NuSep to offer a total Proteomics solution from **Fraction to Function**. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

- **Gels** – NuSep manufactures and sells precast gels including the innovative **ηUView** Gels, which can be visualised 2 minutes after use.
- **Separation Instruments** – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF and is expected to undergo clinical trials later this year.
- **Proteomics Software** – NuSep offers the unique ProteolQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
- **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

NuSep Holdings Ltd
324 Burns Bay Rd
Lane Cove NSW 2066

Postal Address
P.O. Box 823
Lane Cove NSW 1595

Contact Details
Telephone +61 2 8197 3377
Facsimile +61 2 9427 8614

Email info@nusep.com
Web www.nusep.com
ABN 33 120 047 556

Contact:
Prakash Patel
Chief Financial Officer & Company Secretary
+61 2 8197 3377
prakash.patel@nusep.com